Johnson & Johnson

    Jurisdiction
    United States
    LEI
    549300G0CFPGEF6X2043
    ISIN
    US4781601046 (JNJ)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - General

    Scores

    InsiderPie Expert Score
    61 / 100
    Even with peer group:
    62 / 100
    Fair value (Benjamin Graham formula)
    €60.56 168.2% overvalued
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. Read full profile

    Fundamentals

    Net revenue
    €77.30B
    Gross margin
    67.9%
    EBIT
    €18.87B
    EBIT margin
    24.4%
    Net income
    €19.33B
    Net margin
    25.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €83.41B +7.9% €23.33B +20.7%
    €87.50B +4.9% €24.97B +7.0%
    €91.35B +4.4% €26.42B +5.8%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    Last dividend amount
    $1.30
    Ex date
    Payment date
    Dividend payout ratio
    53.3%

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Taubert Jennifer L EVP, WWC. Innovative Medicine -56K $177.81 -$10.04M
    Duato Joaquin CEO and Chairman of the Board -126K $179.21 -$22.55M
    Wolk Joseph J Exec VP, CFO -17K $176.91 -$2.98M
    REED JOHN C EVP, Innovative Medicine, R&D -19K $163.55 -$3.13M

    Congress transactions

    Name Transaction date Value
    Sheri Biggs October 5, 2025 $15.00K–$50.00K
    Richard McCormick September 17, 2025 $1.00K–$15.00K
    Val Hoyle September 12, 2025 $1.00K–$15.00K
    Lisa McClain September 12, 2025 $1.00K–$15.00K
    Julie Johnson September 11, 2025 $1.00K–$15.00K

    Investor transactions

    Name Shares Value Last change Change type
    John D. Spears 438K $72.68M -642K Sell
    Ray Dalio 297K $49.30M -241K Sell
    Peter Brown 203K $33.59M -719K Sell

    Earnings Calls

    Add to watchlist

    Notifications